Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academ...
April 19 2021 - 8:30AM
Business Wire
-Data presentation to be released online at
10:00 AM ET on Friday, April 23, 2021
-Live Q&A session with presenter to be held
on Saturday, April 24, 2021 at 3:00 PM ET
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that
data from the Phase 2b ADVISE trial evaluating the safety and
efficacy of etrasimod, a highly selective, once-daily, oral
sphingosine 1-phosphate (S1P) receptor modulator, in participants
with moderate-to-severe atopic dermatitis (AD), will be presented
during a late-breaking session at the American Academy of
Dermatology Virtual Meeting Experience taking place April 23 - 25,
2021.
Title: Etrasimod, a novel, oral, selective sphingosine
1-phosphate receptor modulator, improves patient and clinician
reported outcomes in adults with moderate-to-severe atopic
dermatitis in a randomized, double-blind, placebo-controlled phase
2 study (ADVISE) Presenter: Dr. Emma Guttman-Yassky
Authors: Emma Guttman-Yassky, Robert Bissonette, Leon
Kircik, Dedee Murrell, Andrew Selfridge, Kris Liu, Gurpreet
Ahuluwalia, Jonathan Silverberg Date/Time: Presentation
released 10:00 AM ET on Friday, April 23, 2021 with Q&A
3:00-4:00 PM ET on Saturday, April 24, 2021 Session:
Late-Breaking Research Session
About Etrasimod
Etrasimod (APD334) is a next generation, once-daily, oral,
highly selective sphingosine 1-phosphate (S1P) receptor modulator
discovered by Arena and designed for optimized pharmacology and
engagement of S1P receptor 1, 4, and 5, which may lead to an
improved efficacy and safety profile.
Etrasimod is intended to provide systemic and local effects on
specific immune cell types and has the potential to treat multiple
immune-mediated inflammatory diseases including ulcerative colitis,
Crohn's disease, eosinophilic esophagitis, atopic dermatitis, and
alopecia areata.
Etrasimod is an investigational compound that is not approved
for any use in any country.
About Arena Pharmaceuticals
ARENA Pharmaceuticals is a team with a singular purpose –
deliver important medicines to patients.
In a rapidly changing global market, we work with a sense of
urgency every day to understand the needs of all our stakeholders,
identify bold, sometimes disruptive, ideas to get medicines to
patients, and relentlessly execute until it's done.
ARENA - Care More. Act Differently.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about etrasimod and
its design and potential, the ADVISE data presentation and live
Q&A, and Arena's purpose, work, understanding, ideas, and
execution. For such statements, Arena claims the protection of the
Private Securities Litigation Reform Act of 1995. Actual events or
results may differ materially from Arena's expectations. Factors
that could cause actual results to differ materially from the
forward-looking statements include those disclosed in Arena's
filings with the Securities and Exchange Commission. These
forward-looking statements represent Arena's judgment as of the
time of this release. Arena disclaims any intent or obligation to
update these forward-looking statements, other than as may be
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210419005128/en/
Corporate Contacts: Patrick Malloy Arena Pharmaceuticals,
Inc. Vice President, Investor Relations & Corporate
Communications pmalloy@arenapharm.com 847.987.4878
Arena Pharmaceuticals (NASDAQ:ARNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arena Pharmaceuticals (NASDAQ:ARNA)
Historical Stock Chart
From Sep 2023 to Sep 2024